Mirum Pharma's Brelovitug Meets Phase 3 Primary Endpoint In AZURE-1 Study For Chronic Hepatitis Delta Virus
– Phase 3 primary endpoint (virologic response and ALT normalization) achieved in both dose arms at Week 24– 48-week data from Phase 2b portion of AZURE-1 demonstrate deepening viral suppression and increased rates of
Mirum's medicine for a serious liver disease worked well in testing. When a company's drug meets its goals in big studies, it shows the medicine might actually help real patients someday.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.